NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The ...

U.S. revenue in the fourth quarter of 2024 was $91.4 million, a decrease of 9.9% compared with $101.5 million in the prior year period. U.S. permanent implant procedures decreased by 7.0% compared ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor ...

Stay up to date on the latest updates from Globus Medical, including progress on FDA clearance for their XR augmented reality headset.

In a surprising move, Globus Medical announced the acquisition of Nevro Corp . (NYSE:NVRO) for $250 million. While initially met with investor skepticism, analysts view this deal as potentially ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Globus Medical (GMED – Research Report) and Nevro Corp (NVRO – Research Report). See what stocks are receiving ...

Globus Medical plans to acquire Nevro Corp, and the $250 million deal aims to tap into another market space in spinal technology, according to a Feb. 20 earnings call. 1. The Nevro acquisition is ...

Globus Medical closed 2024 on a strong note with record financial performance, driven by sales growth, innovative product launches, and strategic acquisitions. The integration of Nevro Corporation ...

The company made another M&A play this month with its planned acquisition of spinal cord stimulation (SCS) company Nevro. “I’m proud of our team at Globus Medical, delivering incredible ...

On a stand-alone basis, Globus Medical reaffirms its full year 2025 revenue guidance range of $2.66 billion to $2.69 billion and fully diluted non-GAAP earnings per share range between $3.40 to $3.50.

Following the consummation of the Nevro, Inc. acquisition, which we expect to close in the late second quarter of 2025, Globus Medical anticipates 2025 net sales of $2.80 billion to $2.90 billion ...